This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Challenges In Managing Women With Epilepsy Discussed On

MAPLE GROVE, Minn., Nov. 27, 2012 /PRNewswire/ -- Approximately 1.5 million women and girls in the United States have epilepsy, of which nearly 500,000 are women of childbearing age. 1,2  Treating women with epilepsy, especially women of childbearing age, presents significant challenges to physicians. [], Upsher-Smith Laboratories, Inc's [] epilepsy-focused educational website, discusses these challenges and provides professional insight by some of the epilepsy community's most respected physicians including Dr. Cynthia Harden, Chief of the Comprehensive Epilepsy Care Center, North Shore University Hospital and Long Island Jewish Medical Center, and Dr. Christopher Skidmore, Director of Neurology Residency/Assistant Professor of Neurology, at Jefferson Medical College of Thomas Jefferson University.

To view the multimedia assets associated with this release, please visit:

"There are several issues that need to be considered when providing treatment to women with epilepsy of childbearing age including: hormonal fluctuations and their effect on epilepsy; drug interactions between oral contraceptives and antiepileptic drugs; and pregnancy," said Dr. Cynthia Harden.  "As clinicians, we need to understand these challenges and identify an appropriate treatment plan unique to each patient."

Dr. Christopher Skidmore added:  "When discussing epilepsy and pregnancy with my female patients, the first and most important thing we discuss is that women with epilepsy can safely have babies and that approximately 95% of babies born to women with epilepsy are born healthy.  There are necessary steps that should be considered to help ensure the patient's and baby's health including: staying on an antiepileptic therapy regimen that is safe for both the patient and her baby; the need for regular office visits throughout the pregnancy; and the benefits of a prenatal vitamin with extra folic acid."

Information available on relating to the treatment of Women with Epilepsy includes:

  • Whitepaper:   Special Considerations for Managing Women with Epilepsy with contributions from Dr. Cynthia Harden The whitepaper focuses on gender-related issues including: oral contraceptives; sexual dysfunction; infertility; birth defects; and other issues relative to the treatment of women with epilepsy.
  • Video:  Treating Women with Epilepsy in the Reproductive Age with personal perspective provided by Dr. Christopher Skidmore .  In the video, Dr. Skidmore discusses pregnancy concerns in women with epilepsy including the need for a higher level of care throughout pregnancy.
  • Podcast:  Women & Epilepsy presented by Dr. Cynthia Harden.  In the podcast, Dr. Harden shares her views on many of the challenges associated with treating women with epilepsy.
  • Additional Women with Epilepsy features include:  frequently asked questions; agree/disagree statements; and an online polling question. is an educational disease website offering healthcare professionals who treat epilepsy some of the latest evidence-based scientific data, dialogue on modern therapy issues, and expert insights by some of the field's most respected clinicians.  The site features regularly updated content including videos, white papers, podcasts, and interactive components addressing various epilepsy-related topics.  In addition to Women with Epilepsy, also features current content related to Epilepsy & Comorbidities, Practice Management & Epilepsy, and Aging & Epilepsy

Upsher-Smith's Expanding CNS Pipeline

Upsher-Smith's central nervous system (CNS) pipeline includes a number of investigational drug programs for various indications within epilepsy, including USL255, USL260, and USL261.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs